| Literature DB >> 25609661 |
Portia N Davis1, Uche Anadu Ndefo2, Ashley Oliver2.
Abstract
OBJECTIVE: To review clinical evidence for the efficacy, safety, and tolerability of dapagliflozin (Farxiga-AstraZeneca), a sodium glucose cotransporter 2 inhibitor, as monotherapy or in combination with other hypoglycemic agents for the treatment of type 2 diabetes. DATA SOURCES: Literature was identified through a systematic MEDLINE search of clinical trial results for dapagliflozin. DATA SYNTHESIS: Multiple controlled clinical trials have established the efficacy, safety, and tolerability of dapagliflozin as monotherapy or in combination with other therapies for type 2 diabetes. Dapagliflozin is approved by Food and Drug Administration as monotherapy or as an add-on to other glucose lowering agents including insulin for the treatment of type 2 diabetes.Entities:
Keywords: ambulatory care; dapagliflozin; endocrinology; internal medicine; sodium glucose co-transporter inhibitor; type 2 diabetes
Mesh：
Substances：
Year: 2015 PMID： 25609661 DOI： 10.1177/0897190014566308
Source DB: PubMed Journal: J Pharm Pract ISSN： 0897-1900